EHA Unplugged
- Episodios
- 204
- Se publica
- cada semana
- Último episodio
- 13 Nov 2026
Sobre el podcast
Discover what's new and what's next in haematology / hematology. Leading experts insights into leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic lymphocytic leukaemia (CLL), stem cell transplantation, sickle cell disease, thalassemia, anemias, CAR T-cell therapy, immunotherapy and more. Unplug from your screen and enjoy the podcasts for and from haematologists / hematologists of the European Hematology Association (EHA).
Episodios 204
Harmonizing Pediatric Hematology Training: the EHA/SIOPe Pediatric Hematology Syllabus
Pediatric hematology training varies widely across Europe. In this podcast episode, Professors Andishe Attarbaschi and Josef Vormoor introduce the new EHA-SIOPe Pediatric Hematology #Syllabus, a shared …
Notas del episodio
Pediatric hematology training varies widely across Europe. In this podcast episode, Professors Andishe Attarbaschi and Josef Vormoor introduce the new EHA-SIOPe Pediatric Hematology #Syllabus, a shared framework for comprehensive, consistent training.
They explain that more than 50 experts contributed to the development of the syllabus, which complements the adult curriculum while addressing pediatric-specific needs.
Attarbaschi describes how the syllabus can help national societies adapt their own training pathways, while Vormoor highlights its modular structure, which allows it to be adapted to different national training systems.
This conversation shows why this syllabus can sustain the foundation for better, more consistent and comprehensive pediatric hematology training across Europe.
The syllabus is open access on the EHA and SIOPe websites: EHA-SIOPe Pediatric Extended Syllabus - The European Hematology Association (EHA).
Guests:
Prof. Josef Vormoor
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
Prof. Andishe Attarbaschi
St. Anna Children’s Hospital, Vienna, Austria
Host:
Isabel Olivera-Martínez, PhD,
Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Integrating Patient Perspectives Into Hematology Care (with Samantha Nier)
The patient voice is no longer optional. Samantha Nier, Chair of the Patient Advocacy Committee (PAC) at EHA and a leader within the Acute Leukemia Advocates Network (ALAN) explains why clinical trials change …
Notas del episodio
The patient voice is no longer optional. Samantha Nier, Chair of the Patient Advocacy Committee (PAC) at EHA and a leader within the Acute Leukemia Advocates Network (ALAN) explains why clinical trials change for the better when patients are involved from the start.
She highlights the importance of involving patients in clinical trial design, informed consent, and research protocols so that care decisions reflect not only scientific goals, but also real-life patient experience, quality of life, and treatment burden.
Samantha shows also how patient organizations contribute to many EHA initiatives, helping to shape guidelines, scientific congress sessions and European-level projects.
A thoughtful discussion about advocacy, inclusion, and the power of listening to the people most affected by disease.
Guests:
Samantha Nier
Affiliation: Chair of EHA's Patient Advocate Committee & Network Director of Acute Leukemia Advocates Network
Host:
Isabel Olivera-Martínez, PhD,
Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How Experts Treat Follicular Lymphoma
Follicular lymphoma (FL) is entering a new era: from decades of chemotherapy to increasingly effective, less toxic biological and immunotherapy-based approaches. In this podcast episode of EHA Unplugged, hear …
Notas del episodio
Follicular lymphoma (FL) is entering a new era: from decades of chemotherapy to increasingly effective, less toxic biological and immunotherapy-based approaches.
In this podcast episode of EHA Unplugged, hear directly from the authors of the latest EHA guidelines on FL: Prof Marco Ladetto (University of Eastern Piedmont, Italy) and Prof Martin Dreyling (LMU Munich, Germany).
They start by discussing the importance of histological confirmation and grading, the role—and current limits—of molecular profiling, and how FLIPI-based risk assessment can inform treatment intensity.
The conversation covers active surveillance for asymptomatic disease, first-line immunochemotherapy, chemo-free options such as rituximab–lenalidomide and novel antibody-based combinations, and sequencing CAR T-cell therapy and bispecific antibodies in later relapses.
The experts also address survivorship, long-term toxicity, patient preferences, and the strategic need to preserve effective options across a potentially decades-long disease course.
Tune in for practical, evidence-based insights to support individualised follicular lymphoma care.
Guests:
Prof Marco Ladetto
University of Eastern Piedmont and SCDU Ematologia, Alessandria, Italy
Prof Martin Dreyling
Ludwig-Maximilian-University, Munich, Germany
Host:
Isabel Olivera-Martínez, PhD,
Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How Experts Treat Chronic Lymphocytic Leukemia (CLL)
Explore the latest EHA guidelines on chronic lymphocytic leukemia (CLL) and Richter transformation with key guideline authors Prof Barbara Eichhorst, hematologist at University Hospital Cologne (Germany), and …
Notas del episodio
Explore the latest EHA guidelines on chronic lymphocytic leukemia (CLL) and Richter transformation with key guideline authors Prof Barbara Eichhorst, hematologist at University Hospital Cologne (Germany), and Prof Paolo Ghia, Director of the CLL Program at Università Vita-Salute San Raffaele (Milan, Italy).
For the first time, the guidelines no longer recommend chemoimmunotherapy when targeted options are available, based on two key advances: the approval of acalabrutinib plus venetoclax with or without obinutuzumab for frontline CLL, and the approval of pirtobrutinib, a non-covalent BTK inhibitor, for relapsed/refractory disease—particularly after prior covalent BTK inhibitor treatment. The guests also make clear that patient selection matters, including TP53 status, IGHV status, comorbidities, co-medications, safety profile, and patient preferences.
Further, the experts highlight a landmark change in how the recommendations were developed: for the first time, patients and patient advocates participated as authors, bringing a patient-centred perspective to treatment decisions, active surveillance, and supportive care.
Tune in for practical insights into personalized CLL management, fixed-duration targeted therapy, treatment sequencing, and the challenges of Richter transformation.
Guests:
Prof Barbara Eichhorst
University of Cologne, Cologne, Germany
Prof Paolo Ghia
Università Vita-Salute San Raffaele, Milano, Italy
Host:
Isabel Olivera-Martínez, PhD,
Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How Experts Treat Hodgkin Lymphoma
Stay up to date with the latest EHA guidelines on Hodgkin lymphoma. In this episode of EHA Unplugged, key guideline authors Prof. Dennis Eichenauer and Prof. Igor Aurer discuss the evidence reshaping the …
Notas del episodio
Stay up to date with the latest EHA guidelines on Hodgkin lymphoma. In this episode of EHA Unplugged, key guideline authors Prof. Dennis Eichenauer and Prof. Igor Aurer discuss the evidence reshaping the management of classic Hodgkin lymphoma.
The discussion highlights the guideline’s central shift: the integration of targeted therapies—brentuximab vedotin and PD-1 inhibitors such as nivolumab—into frontline treatment. The experts explain updated approaches to staging and risk assessment, PET-guided treatment in early-stage disease, BrECADD for younger patients with advanced disease, and nivolumab–AVD for older patients, alongside recommendations for relapsed or refractory disease and autologous stem cell transplantation.
They also consider survivorship, late effects, and the realistic prospects for chemotherapy-free, immune-based approaches.
Tune in for practical, evidence-based insights into improving outcomes while reducing long-term toxicity in Hodgkin lymphoma.
Guests:
Prof. Dennis Eichenauer: University of Cologne, Germany;
First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group, University of Cologne, Cologne, Germany
Prof. Igor Aurer: University Hospital Centre Zagreb, and Medical School, University of Zagreb, Zagreb, Croatia
Host:
Nabil Dorkhom, MD / EHA Head of Education
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How to Improve Equity and Inclusion in Hematology: EHA2026 Diversity, Equity and Inclusion Award
In this episode, Prof Gianluca Gaidano, recipient of the EHA2026 Diversity, Equity and Inclusion Award, explores how promoting equity, inclusion, and access to care has shaped his work within EHA and beyond. He …
Notas del episodio
In this episode, Prof Gianluca Gaidano, recipient of the EHA2026 Diversity, Equity and Inclusion Award, explores how promoting equity, inclusion, and access to care has shaped his work within EHA and beyond. He reflects on educational initiatives in underrepresented regions, including Africa, the Middle East, Asia, and South America, and explains how international collaborations can help expand access to medical knowledge, advanced diagnostics, and innovative therapies.
The discussion explores the difference between drug availability and true patient access, the role of education and patient advocacy in reducing disparities, and how partnerships with local hematology communities can strengthen clinical practice. Prof Gaidano also shares examples from countries such as Bangladesh, Iraq, and Albania, highlighting progress in access to diagnostics, treatments, and specialist training. Listen now for insights into how to contribute to building a more equitable future for hematology.
Guest: Prof Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara, Italy
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Advancing Adult ALL Care in Europe: EHA2026 Clinical Excellence Award
In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have …
Notas del episodio
In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have transformed patient outcomes. He discusses the evolution of treatment for Philadelphia chromosome-positive ALL, from poor survival rates to highly effective targeted and immunotherapy-based approaches, and explains how tyrosine kinase inhibitors, blinatumomab, and chemotherapy-sparing strategies are reshaping care.
The discussion also explores the growing role of measurable residual disease (MRD) monitoring and genetic risk stratification in treatment decision-making, including identifying which patients can safely avoid allogeneic stem cell transplantation. Professor Ribera highlights the impact of collaborative research through PETHEMA, EWALL, and EHA, and shares his perspective on the future of hematology. Listen now for insights into the progress of ALL treatment and a message of optimism for patients and clinicians alike.
Guest: Prof Josep-María Ribera
Josep Carreras Leukemia Research Institute (IJC) and Universitat Autònoma de Barcelona, Spain
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Refining Transplantation and Cellular Therapy: Insights from 2026 Young EHA Award Winner Nico Gagelmann
In this episode, Dr Nico Gagelmann, recipient of the 2026 Young EHA Award, discusses his career in stem cell transplantation and the values that have shaped his work. He explains how multidisciplinary care …
Notas del episodio
In this episode, Dr Nico Gagelmann, recipient of the 2026 Young EHA Award, discusses his career in stem cell transplantation and the values that have shaped his work. He explains how multidisciplinary care, patient selection, graft-versus-host disease prevention, and conditioning strategies can help improve transplant outcomes. The discussion also explores the role of real-world evidence in identifying best practices and supporting efforts to harmonize transplantation approaches across centres.
Dr Gagelmann also highlights the evolving role of CAR T-cell therapy, ongoing disparities in access to innovative treatments, and the importance of collaboration, education, and knowledge sharing across countries. He reflects on building international professional communities, addressing inequalities in hematology care, and ensuring that future advances remain accessible to patients. Listen now for insights into the future of transplantation, cellular therapies, and global hematology collaboration.
Guest: Dr Nico Gagelmann, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, and University Medical Center Hamburg-Eppendorf, Germany
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
What Can We Learn About AML from Clonal Haematopoiesis? | EHA 2026 Research Excellence Award
In this episode, Prof George Vassiliou, recipient of the 2026 EHA Research Excellence Award, discusses how his research has advanced our understanding of clonal haematopoiesis and its relationship to acute …
Notas del episodio
In this episode, Prof George Vassiliou, recipient of the 2026 EHA Research Excellence Award, discusses how his research has advanced our understanding of clonal haematopoiesis and its relationship to acute myeloid leukaemia (AML). He explains how blood stem cells evolve over time, why specific driver mutations promote clonal expansion, and how genetic profiles can help identify individuals at low, intermediate, or high risk of developing myeloid malignancies.
The discussion also explores efforts to translate these discoveries into clinical prevention strategies. Prof Vassiliou highlights emerging risk prediction models, the development of clinics focused on clonal haematopoiesis, and ongoing work to evaluate low-toxicity interventions that could reduce disease progression. He also examines the links between clonal haematopoiesis, cardiovascular disease, immune ageing, and age-related health outcomes, offering insights into the future of early detection and preventive approaches in haematology. Listen now for perspectives on how understanding clonal haematopoiesis may help reshape the prevention of AML and other age-related diseases.
Guest: Prof George Vassiliou, Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Improving MPNs management: EHA2026 Lifetime Achievement Award
In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She …
Notas del episodio
In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She reviews the major scientific and clinical developments she has witnessed over more than two decades, including the discovery of JAK2, MPL and CALR mutations, the evolution of diagnostic criteria, and the emergence of targeted therapies for MPNs.
The discussion explores landmark studies that helped shape current clinical practice, including PT-1, COMFORT-II and MAJIC-PV, as well as the growing role of patient advocacy in driving research and improving care. Prof Harrison also looks ahead to the next generation of therapies, including CALR-targeted immune approaches and combination treatment strategies, while highlighting the challenges and opportunities that remain for patients with MPNs. Listen now for insights from one of the leading figures in the field.
Guest: Prof Claire Harrison
Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
CAR T Toxicities in Focus: What We Have Learned from Registry Data
In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients …
Notas del episodio
In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have helped improve early toxicities such as cytokine release syndrome (CRS) and ICANS awareness and management as well as helped recognise and address longer-term effects. She further explores the growing understanding of immune effector cell-associated hematotoxicity (ICAHT) and the importance of risk prediction and early intervention.
Dr Ruggeri also discusses emerging safety questions as CAR T use expands, including secondary malignancies, long-term immune effects, and fertility outcomes. She highlights encouraging registry findings showing that fertility recovery and successful pregnancies are possible after CAR T therapy, offering renewed hope for patients seeking to return to normal life following treatment. Listen now for valuable insights into how registries, collaboration and long-term follow-up are helping improve cellular therapy.
Guest:
Dr Annalisa Ruggeri
Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
Chair of the Cellular Therapy and Immunobiology Working Party (Education Portfolio), EBMT
Host: Leah DeLeon
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Life After YERM: How the Young EHA Research Meeting Shaped Careers
In the final episode of our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM), we explore how the meeting acts as a powerful launching pad for scientific careers. We talk to …
Notas del episodio
In the final episode of our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM), we explore how the meeting acts as a powerful launching pad for scientific careers. We talk to 2018 YERM speakers Dr. Lorena Arranz and Dr. Mattias Carlsten to hear about their experiences presenting their research at YERM. Looking back on their journeys, they share valuable advice and lessons learned at YERM to help guide today's early-career researchers.
Guests:Dr Mattias Carlsten, Karolinska Institutet and Karolinska University Hospital, Sweden
Dr. Lorena Arranz, University of Oslo and Oslo University Hospital, Oslo, Norway
Host: Rhiannon Newman, MSc, University of Helsinki and Young EHA committee
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Discover YERM: The Young EHA Research Meeting and Your Place in It
Welcome to our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM) with an introduction to its history and mission. We sit down with co-founder Prof Ruud Delwel and current …
Notas del episodio
Welcome to our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM) with an introduction to its history and mission. We sit down with co-founder Prof Ruud Delwel and current organizer Prof Marlies Vanden Bempt to discuss how YERM is tailored to empower early-career researchers. Together, we reflect on a decade of growth and share their vision for the future of YERM.
Guests:
Prof Ruud Delwel, Erasmus Medical Centre, The Netherlands
Prof Marlies Vanden Bempt, KU Leuven, Belgium
Host: Rhiannon Newman, MSc, University of Helsinki and Young EHA committee
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
CAR-T for Pediatric B-ALL: Expert Tips
In this episode, Prof André Baruchel discusses the role of CAR T-cell therapy in children with B-cell acute lymphoblastic leukemia (B-ALL). He reviews current indications for CAR T-cell treatment, including …
Notas del episodio
In this episode, Prof André Baruchel discusses the role of CAR T-cell therapy in children with B-cell acute lymphoblastic leukemia (B-ALL). He reviews current indications for CAR T-cell treatment, including relapsed and refractory disease, and explores whether CAR T could move earlier in the treatment pathway. The discussion also examines how CAR T-cell therapy compares with transplantation, blinatumomab, and other salvage strategies, as well as the factors that influence long-term outcomes and relapse risk.
The conversation highlights key questions surrounding the role of allo-HSCT in the CAR T era. Prof Baruchel also explores emerging approaches designed to improve outcomes, including dual-targeted CARs, strategies to enhance cellular persistence.
Listen now for insights into how fourth-generation CAR constructs that modify the tumour microenvironment, and in vivo CAR therapies may further transform the treatment of pediatric B-ALL.
Guests: Prof André Baruchel
Affiliation: Professor of Pediatrics, Université Paris-Cité; former Head of the Pediatric Hematology Immunology Department, Hôpital Robert-Debré, Paris
Host: Leah DeLeon
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Getting Patients to CAR T: Referral Systems in Europe
In this episode of EHA Unplugged, Prof Marion Subklewe discusses one major challenge facing CAR T-cell therapy in Europe: ensuring that eligible patients are referred for treatment. She explains how access has …
Notas del episodio
In this episode of EHA Unplugged, Prof Marion Subklewe discusses one major challenge facing CAR T-cell therapy in Europe: ensuring that eligible patients are referred for treatment. She explains how access has improved since the first CAR T-cell approvals, but highlights that many eligible patients still do not receive these potentially curative therapies. The discussion explores differences between European healthcare systems, barriers to referral, and persistent misconceptions about patient eligibility.
Prof Subklewe advocates for structured referral pathways and multidisciplinary boards that assess all eligible patients in collaboration with CAR T-cell experts. She argues that treatment eligibility should not depend solely on individual physicians and highlights the benefits of coordinated networks, shared decision-making, professional education, and patient engagement.
Listen now for insights into how stronger referral systems could help more patients access CAR T-cell therapy across Europe.
This podcast episode is supported by Bristol Myers Squibb.
Guests: Prof Marion Subklewe
Affiliation:
LMU – University Hospital, LMU Munich
Department of Hematology/Oncology
LMU- Gene Center Munich
Laboratory of Translational Cancer Immunology
Germany
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Outpatient CAR T in Europe: Lessons from Barcelona
In this episode, Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz discuss how their team at Hospital Clínic de Barcelona has developed a fully outpatient programme for CAR T-cell therapy. They explain …
Notas del episodio
In this episode, Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz discuss how their team at Hospital Clínic de Barcelona has developed a fully outpatient programme for CAR T-cell therapy. They explain the evolution of their at-home programme, from outpatient transplantation and supportive care to outpatient CAR T administration, and describe the key clinical and logistical requirements for patient selection. The discussion explores caregiver training, monitoring for cytokine release syndrome and neurotoxicity, and the importance of dedicated multidisciplinary teams.
The guests also share their experience with outpatient CAR T across academic and commercial products, highlighting safety outcomes, early discharge strategies, resource utilisation, and patient-centred benefits. They discuss practical considerations for centres interested in establishing similar programmes, including infrastructure, staffing, legislation, and continuous evaluation. Listen now for insights into the opportunities and challenges of delivering CAR T therapy beyond the hospital ward.
This podcast episode is supported by Bristol Myers Squibb.
Guests: Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz
Affiliation: Hospital Clínic de Barcelona, Spain
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Smarter CARs: Using AI to Improve Chimeric Antigen Receptor Design
Artificial intelligence is opening new possibilities in the design of next-generation immunotherapies. In this episode of EHA Unplugged, Dr Andrea Schmidts discusses how AI-driven approaches are reshaping the …
Notas del episodio
Artificial intelligence is opening new possibilities in the design of next-generation immunotherapies. In this episode of EHA Unplugged, Dr Andrea Schmidts discusses how AI-driven approaches are reshaping the development of chimeric antigen receptor (CAR) T-cell therapies, particularly at the design stage of the CAR receptor binding domains.
Dr Schmidts explains how structure-based AI models can generate entirely new protein binders, moving beyond the traditional reliance on monoclonal antibody–derived fragments. The conversation explores how these tools enable large-scale exploration of CAR designs, the experimental challenges of validating thousands of candidates, and the potential to tailor therapies that overcome resistance mechanisms such as antigen escape. Looking ahead, Dr. Schmidts highlights the role of AI across the entire CAR T-cell development pipeline—from early design to testing and manufacturing—and reflects on the practical and regulatory considerations of bringing AI-designed therapies to the clinic.
Guest: Dr Andrea Schmidts
Affiliation: Emmy Noether Group Leader, Medicine III – Hematology/Oncology, Technical University of Munich, Germany
Host: Leah de Leon
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
What is Real-World Evidence Revealing About CAR T Therapy?
In this episode, Prof Benoit Tessoulin examines how real-world evidence from the French DESCAR-T registry is expanding our understanding of CAR T-cell therapy beyond clinical trials. He explains how the …
Notas del episodio
In this episode, Prof Benoit Tessoulin examines how real-world evidence from the French DESCAR-T registry is expanding our understanding of CAR T-cell therapy beyond clinical trials. He explains how the registry captures data from patients considered for CAR T-cell treatment, including those who do not ultimately receive therapy, and explores what these data reveal about patient selection, treatment outcomes, bridging therapy, and comparisons between different CAR T-cell products.
The discussion also examines how real-world populations differ from clinical trial cohorts, in what measure registry data have confirmed the effectiveness of CAR T-cell therapy in routine practice, and what has been learned about toxicities such as CRS, ICANS, and infections. Prof Tessoulin highlights the importance of timely referral, evolving product selection strategies, and the growing role of patient registries in informing clinical decision-making and future research. Listen now for insights into how real-world data are informing CAR T-cell therapy updates.
This podcast episode is supported by Bristol Myers Squibb.
Guest: Prof Benoit Tessoulin
Affiliation: Hematology Department, Centre Hospitalier Universitaire Nantes, France
Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Hematology Portraits: Prof Frank Leebeek
In this episode Prof. Frank Leebeek reflects on his career in hematology, highlighting a lifelong commitment to bridging clinical practice and research. From his early interest in fibrinolysis during medical …
Notas del episodio
In this episode Prof. Frank Leebeek reflects on his career in hematology, highlighting a lifelong commitment to bridging clinical practice and research.
From his early interest in fibrinolysis during medical school to his current role as Chair of the Department of Hematology at Erasmus Medical Center and Board member at EHA, Prof. Leebeek shares how a dual commitment to research and patient care has shaped his path.
The conversation explores key milestones in bleeding disorders research, including large-scale studies on von Willebrand disease that helped improve awareness, diagnosis, and patient-reported outcomes. Prof. Leebeek also discusses his involvement in pioneering gene therapy trials for hemophilia, which have transformed treatment paradigms and patients’ quality of life, while noting ongoing challenges in access and affordability. Beyond research, he reflects on the importance of collaboration, the value of long-term patient relationships, and the role of European-level initiatives in advancing hematology care.
Tune in to hear insights from a leading figure in benign hematology and learn how sustained collaboration and innovation continue to drive progress in the field.
Guest: Prof Frank Leebeek
Affiliation: Erasmus Medical Center, Rotterdam, The Netherlands
Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How to Start a Clinical Trial?
What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged, Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal …
Notas del episodio
What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged, Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal investigator, and how the EHA Clinical Research Training in Hematology (CRTH) program helped shape his path.
Prof. Mai reflects on the practical and often underappreciated challenges of clinical trial design—from budgeting and statistical planning to ethical considerations and regulatory requirements. He highlights the importance of mentorship and peer networks, as well as the need for persistence when ideas are ahead of their time. The conversation also explores the skills hematologists need to get started in clinical research, with a clear message: developing trials is a multifaceted process that requires both scientific expertise and hands-on learning.
Whether you are early in your career or considering a move into clinical research, this episode offers valuable insights into how to take the first steps, overcome challenges, and ultimately contribute to improving patient care through clinical trials.
Guests:
Prof Elias K. Mai
Heidelberg University Hospital, Heidelberg, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How Experts Treat Multiple Myeloma
In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and …
Notas del episodio
In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma.
The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibody-drug conjugates—have reshaped the treatment landscape and informed the latest recommendations. The experts discuss the integration of novel prognostic tools such as minimal residual disease (MRD), circulating tumour cells and mass spectrometry, and their evolving role in risk stratification.
The episode also reviews key recommendations for frontline management and provides practical guidance for selecting therapies in relapsed and refractory multiple myeloma. Throughout the discussion, the speakers highlight how the updated guidelines support clinicians in navigating an increasingly complex therapeutic landscape.
Guests:
Prof. Meletios Dimopoulos and Prof. Evangelos Terpos
National and Kapodistrian University of Athens, Greece
Host: Prof. Pieter Sonneveld
Erasmus University Medical Center, Rotterdam, The Netherlands
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Where Are We Now With Immunotherapy in Multiple Myeloma?
Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. In this episode, Dr. Paula Rodriguez Otero discusses …
Notas del episodio
Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.
In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities.
Guests:
Dr Paula Rodríguez-Otero
Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Menin Inhibitors to Treat Acute Myeloid Leukemia (AML)
Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which …
Notas del episodio
Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation.
In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition, identify which AML patient populations are most likely to benefit, and review the current clinical evidence supporting their use in defined molecular subtypes.
Guests:
Dr Scott Armstrong
Dana-Farber Cancer Institute
Prof Marc Raaijmakers
Erasmus Medical Center
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How Experts Treat HIV-associated Lymphomas
Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas. In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having …
Notas del episodio
Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas.
In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments.
This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL, Burkitt lymphoma, plasmatic lymphoma, and more.
Finally, Prof Hubel advocates for the inclusion of people living with HIV in lymphoma clinical trials to increase evidence base on HIV-associated lymphomas and improve the care for this specific patient populations.
Link to the guideline: Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - Hübel - 2024 - HemaSphere - Wiley Online Library
Guest: Prof Kai Hübel
Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Hematology Portraits: Associate Prof Meritxell Alberich Jordà
Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played …
Notas del episodio
Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia.
Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding about leading a lab. Tune in to hear what she wishes she’d known at the very beginning of her journey.
Guest: Associate Prof Meritxell Alberich Jordà
Institute of Molecular Genetics of the Czech Academy of Sciences, Laboratory of Haematooncology Head, Prague, Czech Republic The Childhood Leukaemia Investigation Prague in the Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How Experts Treat Large B-cell Lymphoma (LBCL)
Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up …
Notas del episodio
Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library).
Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines, walk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up.
Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our guests explain treatment strategies for first-line and relapse/refractory patient populations, highlighting the practice-changing introduction of CAR T therapy in second-line for eligible patients. Finally, they discuss the disparities of access to innovative treatments across Europe and explore future perspectives of LBCL management in Europe and beyond.
Guests: Prof Catherine Thieblemont and Prof Marie José Kersten.
Professor Catherine Thieblemont from Saint-Louis Hospital in Paris.
Professor Marie José Kersten from Amsterdam University Medical Centers (UMC)
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Connecting Hematology Research and Real Life: Peter Kapitein
In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights …
Notas del episodio
In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies.
Guest: Peter Kapitein
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Guest: Peter Kapitein
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How Experts Treat Peripheral T- and NK-cell Lymphomas
Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis …
Notas del episodio
Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy).
In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell lymphomas.
Our guests explain the conscious effort of the guidelines panel to provide evidence based detailed recommendations for each subtype of PTCLs to improve diagnosis, treatment, and follow up. The emphasis is on moving away from “one size fits all” DLBCL style approach toward entity- adapted strategies.
Throughout the conversation, they stress the need to read the full guideline – including the supplementary material – and the importance of a multidisciplinary approach by experienced hematopathologists, ideally in expert or reference centres to give patients the best chance of appropriate, modern therapy.
GuestS: Prof Francesco D'Amore and Prof Massimo Federico.
Professor Francesco D'Amore is a Clinical Professor and Chair of the Department of Hematology at Aarhus University in Denmark
Professor Massimo Federico is a Senior Professor of Medical Oncology at the University of Modena and Reggio Emilia in Italy
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Hematology Portraits: Prof Konstanze Döhner
Join EHA President Prof Konstanze Döhner from University Hospital Ulm in Germany as she discusses her deep interest in hematology, both in research and in the clinics. Listen as Prof. Döhner shares why she …
Notas del episodio
Join EHA President Prof Konstanze Döhner from University Hospital Ulm in Germany as she discusses her deep interest in hematology, both in research and in the clinics.
Listen as Prof. Döhner shares why she decided to focus on Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPNs) in her career as a medical doctor, a researcher and a educator. Tune in to hear Prof. Döhner describe her journey to becoming the EHA president and her reflections on the current challenges in the hematology field and the solutions she proposes to address those.
Guest: Prof Konstanze Döhner, University Hospital Ulm, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
How Blood Cells Age: From Stem Cells to Clones (with Dr Michael Milsom)
In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic …
Notas del episodio
In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic andimmune aging that does not focus solely on HSCs. He describes how inflammation‑driven stem cell activation and proliferation cause functional attrition and clonalselection of HSCs, contributing to clonal hematopoiesis.
Learn about the mechanisms of blood cells aging andpotential interventions to slow down the process.
Guest: Dr Michael Milsom
Head of the Division of Experimental Hematology at the German Cancer Research Center, (DKFZ), and group leader at the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‑STEM), Heidelberg, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Aquí están los 40 episodios más recientes de 204. Los anteriores están en el feed del podcast.
Podcasts similares
Más podcasts de Ciencias
¿Es tu podcast?
Confírmalo con una entrada en tu feed: aquí recibes un código, lo añades como podcast:txt en el canal de tu feed y nosotros lo comprobamos. Después tu podcast aparecerá como «verificado» en SoundNode.